- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 30, 2023Minnesota Attorney General Keith Ellison and Robins Kaplan Partner Tara Sutton Give Opening Statements in Minnesota’s Lawsuit Against JUUL
March 28, 2023Robins Kaplan LLP Announces 2023 Leadership Council on Legal Diversity (LCLD) Fellow and Pathfinder
March 22, 2023Benchmark Litigation Names Robins Kaplan 2023 Minnesota Law Firm of the Year
April 3, 2023Conference of Tribal Lending Commissioners
April 11-13, 2023Mass Torts Made Perfect Seminar
April 19, 2023FBA Women in MDL, Mass and Class Leadership
March 2023Unintended Consequences of Banning Noncompete Agreements
March 26, 2023What I’ll Be Watching for in the Amgen Oral Arguments
March 2023How an Investor Can Lose More Than Just Their Investment
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Jake Holdreith, Robins Kaplan Shortlisted For LMG Life Sciences Awards
July 28, 2022
Robins Kaplan LLP is pleased to announce that Jake Holdreith has been named to LMG Life Sciences 2022 shortlist for Hatch-Waxman Litigator of the Year – Generic. Only six attorneys in the country were recognized on this list. Additionally, the firm was shortlisted for Hatch-Waxman Litigation Firm of the Year – Generic, as well as for Inter-Partes Review Firm of the Year.
Holdreith is a member of the firm’s executive board. He has tried jury cases to multi-million dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Holdreith counsels clients and tries complex lawsuits in a range of practice areas. He is known for work in in the pharmaceutical, chemical, and electronics industries and has handled cases in the United States, Europe, and Asia.
Holdreith has previously been recognized by LMG Life Sciences as a “Life Sciences Star” and as “General Patent Litigator of the Year.” He was also the recipient of the “Hatch Waxman Impact Cases of the Year” award in 2016.
The firm’s Intellectual Property and Technology Group works across the full spectrum of Hatch-Waxman/ANDA matters, as well as strategic litigation-focused counseling during due diligence and formulation development, and in pharmaceutical-related antitrust matters. The group represents biosimilar, 505(b)(2) and ANDA filers in actions defending patent infringement, asserting patents, before the PTAB and challenging FDA action, in antitrust actions, as well as in business transactions.
You can find a complete list of the nominees here. The winner of this year’s award will be announced at a ceremony in New York City on September 8, 2022.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.